Trial Profile
A Randomized, Prospective, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 01 Mar 2021 Status changed from active, no longer recruiting to completed.
- 08 Jul 2020 Planned End Date changed from 1 Dec 2019 to 31 Dec 2020.
- 08 Jul 2020 Planned primary completion date changed from 1 Dec 2019 to 31 Dec 2020.